tiprankstipranks
Ionis Pharmaceuticals price target raised to $62 from $60 at Piper Sandler
The Fly

Ionis Pharmaceuticals price target raised to $62 from $60 at Piper Sandler

Piper Sandler analyst Do Kim raised the firm’s price target on Ionis Pharmaceuticals to $62 from $60 and keeps an Overweight rating on the shares. Eplontersen, the company’s investigational medicine to treat transthyretin amyloidosis, continues to be a key driver of share value, Kim tells investors. FDA acceptance of eplontersen is expected in Q1. The company is expected to reveal data from the drug’s NEURO study in mid-2023 and this should be a catalyst, the analyst said. Kim adds olezarsen should be Ionis’ next commercial product and Phase 3 data is expected in the second half of this year.

Published first on TheFly

See Insiders’ Hot Stocks on TipRanks >>

Read More on IONS:

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100
Bitcoin

Popular Articles